[Research progress on albumin therapy for hepatic encephalopathy]

Area of Science:

• Hepatology
• Neurology
• Gastroenterology

Background:

• Hepatic encephalopathy (HE) is a severe complication of decompensated cirrhosis, characterized by neurological and psychiatric dysfunction.
• Pathogenesis involves complex factors including ammonia toxicity, oxidative stress, inflammation, and gut dysbiosis.
• Current treatments for HE lack specificity, with options like lactulose, rifaximin, and supportive therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of human albumin as a treatment for hepatic encephalopathy.
• To assess the impact of human albumin on cognitive function and quality of life in HE patients.

Main Methods:

• Review of recent research and clinical studies on human albumin therapy for HE.
• Analysis of treatment outcomes, including cognitive improvements and quality of life metrics.

Main Results:

• Human albumin demonstrated safety and effectiveness in treating hepatic encephalopathy.
• Significant improvements were observed in patients' cognitive function.
• Enhanced quality of life was reported in patients receiving human albumin treatment.

Conclusions:

• Human albumin represents a promising therapeutic option for hepatic encephalopathy.
• This treatment offers benefits beyond cognitive enhancement, positively impacting overall patient well-being.
• Further research may solidify human albumin's role in managing HE complications.